Appearing as a noteworthy development in the battle against obesity, this medication is generating considerable buzz. This treatment combines properties of two established GLP-1 receptor agonists, liraglutide, with an new glucose-dependent peptide component. Initial clinical results have shown substantial body loss in individuals with excessive… Read More